COPENHAGEN (Reuters) -Bavarian Nordic said on Thursday it could supply 13 million doses of its mpox vaccine by the end of 2025, up from a previous forecast of 10 million doses, and is exploring options to significantly expand its capacity.
The Danish biotech company said it had also identified measures that could boost supply by another 50 million doses within the next 12-18 months, subject to regulatory approvals and market demand.
“The Company continues to explore additional levers that could further expand the capacity. This includes looking to transfer manufacturing to other companies either in Africa or other parts of the world,” it said in a statement.
(Reporting by Stine Jacobsen, editing by Essi Lehto and Terje Solsvik)
Comments